In a phase II clinical trial involving patients with recurrent platinum-sensitive ovarian cancer, irrespective of the BRCA1/2 mutation, primary peritoneal cancer, and fallopian tube cancer, the overall incidence of anemia was 17%, whereas that of grade ≥3 anemia was 5% when olaparib was used as maintenance therapy (7). This evidence concerns the gene BRCA1 and anemia.